Interline raises $92M for drug discovery of dysfunctional proteins
May 14, 2021 -- Interline Therapeutics has raised $92 million to be used to expand its research platform and advance six preclinical therapeutic programs. Read More
NanoCellect launches new cell sorter
May 14, 2021 -- NanoCellect Biomedical announced it has scheduled a virtual launch for its Wolf G2 Cell Sorter. Read More
VBI touts positive hepatitis B vaccine results
May 12, 2021 -- VBI Vaccines' prophylactic 3-antigen hepatitis B vaccine candidate offers better protection from the disease than the mono-antigenic vaccine Engerix-B, according to phase III study results. Read More
Cellectis, Sanofi partner on UCART clinical trials
May 12, 2021 -- Sanofi has agreed to supply anti-CD52 monoclonal antibody alemtuzumab for use in a lymphodepleting regimen in Cellectis-sponsored universal chimeric antigen receptor T-cell (UCART) trials. Read More
Appia Bio launches to develop stem cell-based cell therapies
May 11, 2021 -- Appia Bio has launched from stealth as an early-stage biotechnology company focused on the development of engineered allogeneic cell therapies from hematopoietic stem cells for cancer patients. The company will be initially backed by $52 million in financing. Read More
FDA authorizes Pfizer-BioNTech COVID-19 vaccine for adolescents
May 11, 2021 -- The U.S. Food and Drug Administration (FDA) expanded the emergency use authorization (EUA) for the Pfizer-BioNTech COVID-19 vaccine to include adolescents ages 12 to 15 years. Read More
Novavax posts positive preclinical results for flu/COVID-19 vaccine
May 10, 2021 -- Novavax is highlighting positive preclinical results for a combination influenza/COVID-19 vaccine. Read More
Inovio touts COVID-19 phase II vaccine results
May 10, 2021 -- Inovio is highlighting results from its phase II clinical trial evaluating its COVID-19 DNA vaccine. Read More
Altimmune's intranasal COVID-19 vaccine shows sterilizing potential
May 10, 2021 -- Preclinical data for Altimmune's intranasal AdCOVID vaccine candidate show the drug has sterilizing immunity potential after a single dose. Read More
SARS-CoV-2 vaccine candidate shows promise against variants
May 10, 2021 -- A pancoronavirus vaccine candidate created by the Infectious Disease Research Institute, the Duke Human Vaccine Institute, and 3M shows potential to protect against variants of SARS-CoV-2, according to a study published May 10 in Nature. Read More
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter